Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK candidate MMR vaccine versus M-M-R II with co-administered HAV, varicella, and pneumococcal vaccines in children 12-15 months old
2011-005860-31Phase 2
- Sponsor
- GSK
- Start
- Jun 2015
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of measles, mumps, and rubella vaccine, M-M-R II, Hepatitis A virus vaccine, varicella virus vaccine live and pneumococcal conjugate vaccine in measles, mumps, rubella and 3 more (2 arms), sponsored by GSK. Primary endpoints: Anti-measles virus antibody concentration at Day 42, Anti-mumps virus antibody titer at Day 42 and 1 more.
02
Drugs
measles, mumps, and rubella vaccineM-M-R IIHepatitis A virus vaccinevaricella virus vaccine livepneumococcal conjugate vaccine
03
Conditions
measlesmumpsrubellachickenpoxhepatitis A (HAV)
Beyond the preview
Go deeper on 2011-005860-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005860-31.